Ferroptosis Research in Age-Related Macular Degeneration

Ferroptosis Research in Age-Related Macular Degeneration

Ferroptosis in Ocular Pathology: Mechanism, Pathogenesis in Age-Related Macular Degeneration (AMD), and Translational Therapeutic Avenues

I. Introduction to Regulated Cell Death and the Ocular Context

Age-related Macular Degeneration (AMD) represents a leading cause of irreversible vision loss in the elderly population worldwide. Its multifaceted pathology involves genetic factors, chronic oxidative stress, and the progressive degeneration of the Retinal Pigment Epithelium (RPE) and photoreceptors. Recent advances in cell biology have established that cell death in AMD is not solely restricted to traditional apoptosis or necrosis, but critically involves regulated necrosis pathways such as ferroptosis. Understanding the unique biochemical and metabolic pressures within the posterior segment of the eye is essential to appreciate why ferroptosis is such a profound driver of ocular pathology.

A. The Unique Metabolic and Oxidative Vulnerability of the Retina

The retina is a tissue with exceptional metabolic demands, exhibiting one of the highest oxygen consumption rates in the body. This intense metabolic activity inherently leads to a chronically high baseline level of Reactive Oxygen Species (ROS) generation, creating a significant oxidative burden.

The structural composition of the photoreceptors exacerbates this vulnerability. Photoreceptor outer segments (POS) are uniquely rich in polyunsaturated fatty acids (PUFAs). These PUFAs serve as the principal substrate for lipid peroxidation, making retinal cells acutely susceptible to ferroptosis, a cell death mechanism defined by the exhaustion of lipid-detoxifying systems.

Furthermore, the integrity of the RPE, the cell layer beneath the photoreceptors, is constantly challenged. The RPE must continuously phagocytose and process the shed POS, which contain photosensitive groups, various oxidants, and highly unsaturated fatty acids. This strenuous phagocytic process increases intrinsic ROS production. With aging, a primary risk factor for AMD, the number of dysfunctional mitochondria increases within the RPE, leading to a significant acceleration of ROS generation and magnifying the chronic oxidative stress. Ferroptosis, therefore, is ideally positioned to execute RPE cell demise in this inherently oxidative, lipid-rich environment because it directly targets the systems designed to manage membrane lipid hydroperoxides.

B. Ferroptosis: Definition, Morphology, and Scope in Ocular Disease

Ferroptosis is recognized as a specific, iron-dependent form of regulated cell death characterized by the massive accumulation of toxic lipid hydroperoxides. The discovery and definition of ferroptosis have allowed researchers to differentiate it mechanistically and morphologically from other common cell death pathways, such as apoptosis, necroptosis, and autophagy.

Morphologically, ferroptosis is distinct. Affected cells often maintain a normal size but exhibit specific mitochondrial changes, including shrinking, increased membrane density, and a reduction or absence of mitochondrial cristae. This contrasts sharply with the nuclear condensation characteristic of apoptosis. Biochemically, ferroptosis is triggered when large amounts of unsaturated fatty acids within the cell membrane undergo uncontrolled lipid peroxidation, catalyzed by ferrous iron (Fe2+) or lipoxygenases (LOX).

Ferroptosis is now implicated as a key pathological factor across a wide spectrum of ophthalmological disorders, extending beyond AMD to include Diabetic Retinopathy (DR), Glaucoma, Retinal Ischemia-Reperfusion (RIR) injury, Retinitis Pigmentosa (RP), and Retinoblastoma.

II. The Core Molecular Mechanism of Ferroptosis

The mechanisms governing ferroptosis center on a highly sensitive balance between intracellular iron handling and radical scavenging systems. Disruption of this balance leads to catastrophic oxidative damage to cellular membranes.

A. The Central Role of Iron Metabolism and the Fenton Reaction

Dysregulation of intracellular iron homeostasis is the critical initiating step of ferroptosis. In AMD, abnormal iron accumulation has been widely reported in the retinal tissue and aqueous humor, highlighting its significance in the disease pathogenesis.

Free intracellular ferrous iron (Fe2+) is the essential catalyst in this process. In the presence of oxidative stress, Fe2+ reacts with hydrogen peroxide (H2O2), a form of ROS, through the highly reactive Fenton reaction, expressed by the chemical equation:

Fe2++H2O2→Fe3++HO∙+HO−

This reaction generates the highly toxic hydroxyl radical (HO∙), which is capable of indiscriminate damage. These radicals rapidly initiate the uncontrolled peroxidation of PUFAs within cell membranes, leading to loss of membrane integrity, mitochondrial dysfunction, and ultimately, ferroptotic cell death. The dependence on free iron implies that therapeutic strategies must address iron chelation and sequestration in addition to direct antioxidant action.

B. Regulation of Ferroptosis: The Principal Antioxidant Pathways

Cellular defense against ferroptosis relies on parallel systems designed to neutralize lipid hydroperoxides before they can propagate widespread membrane damage.

1. The System Xc–/GSH/GPX4 Axis: The First Line of Defense

The classic regulatory pathway focuses on Glutathione Peroxidase 4 (GPX4). GPX4 is a specialized enzyme that utilizes reduced glutathione (GSH) to detoxify lipid hydroperoxides (L-OOH), converting them into harmless lipid alcohols (L-OH). The production of GSH, in turn, is critically dependent on the uptake of cystine, which is mediated by the System Xc− antiporter.

Pharmacological induction of ferroptosis, such as by Erastin, often works by inhibiting System Xc−, thereby depleting intracellular GSH stores and indirectly inactivating GPX4. Alternatively, inhibitors like RSL3 directly target and inactivate GPX4. Genetic knockout of GPX4 similarly results in excess intracellular lipid peroxide accumulation and swift cell death. While GPX4 is an important target, focusing solely on this axis presents translational difficulties due to challenges with inhibitor selectivity, potential systemic toxicity, and the inherent capacity of cancer cells—and potentially RPE cells—to activate compensatory mechanisms.

2. The FSP1/NADPH/CoQ10 Pathway: GPX4-Independent Protection

The discovery of Ferroptosis Suppressor Protein 1 (FSP1) defined a crucial alternative pathway operating independently and parallel to the GPX4 system. FSP1 utilizes NADPH to catalyze the continuous regeneration of Coenzyme Q10 (CoQ10).

Regenerated CoQ10 is a lipophilic free-radical scavenger that effectively inhibits lipid peroxidation directly within the cellular membrane. This FSP1/NADPH/CoQ10 pathway is essential because it provides robust cellular protection even in conditions where GPX4 activity is compromised or entirely absent. Consequently, designing effective therapeutic agents requires addressing the possibility of FSP1 upregulation or compensation when GPX4 is inhibited, suggesting that a successful approach must either overwhelm both pathways or bypass them entirely using direct radical-trapping methods.

3. The Complexity of Mitochondrial Regulation (DHODH)

Mitochondrial integrity and metabolic state also influence ferroptosis sensitivity. The enzyme Dihydroorotate Dehydrogenase (DHODH) is known to synergize with the GSH-GPX4 antioxidant axis to mitigate mitochondrial lipid peroxidation. However, the exact mechanism by which DHODH inhibits ferroptosis remains subject to ongoing debate and appears linked to the involvement of the parallel FSP1 pathway, underscoring the delicate and complex equilibrium regulating mitochondrial and cytosolic defenses against this cell death modality.

Table 1: Key Molecular Regulators and Pathways of Ferroptosis

Pathway Component	Role/Function	Mechanism in Ferroptosis Induction	Relevance to Ocular Disease
GPX4 (Glutathione Peroxidase 4)	Detoxifies toxic lipid hydroperoxides (L-OOH) to lipid alcohols (L-OH)	Inhibition or GSH depletion leads to lipid ROS accumulation	Primary enzymatic defense against ferroptosis in RPE/Retina
System Xc−(Cystine/Glutamate Antiporter)	Controls intracellular Cysteine/GSH synthesis	Inhibition (e.g., by Erastin) depletes GSH, indirectly inactivating GPX4	Targeting limited by FSP1 redundancy and poor selectivity
FSP1 (Ferroptosis Suppressor Protein 1)	GPX4-independent anti-peroxidation defense	Catalyzes CoQ10 regeneration via NADPH to scavenge lipid ROS directly	Confers resistance to GPX4-targeting drugs
Iron (Fe2+)	Essential catalyst for ROS generation	Drives the Fenton reaction with H2O2 to produce highly reactive hydroxyl radicals (HO∙)	Abnormal accumulation is a hallmark of AMD pathology

III. Ferroptosis in Ocular Pathophysiology: Expanding the Clinical Context

The role of ferroptosis extends beyond AMD, establishing it as a common mechanistic endpoint triggered by fundamentally diverse ocular stressors, including metabolic dysfunction and ischemia.

A. Ferroptosis in Ischemic and Microvascular Diseases

Ferroptosis is a prevalent component of Retinal Ischemia-Reperfusion (RIR) injury. RIR, characterized by initial restriction of blood supply followed by reperfusion, is a pathological factor in conditions such as acute glaucoma, ischemic optic neuropathy, and retinopathy of prematurity.

The intervention studies in RIR models have provided robust validation for therapeutic strategies targeting ferroptosis. Specifically, the iron chelator Deferoxamine has been shown to alleviate retinal ischemia-reperfusion injury by inhibiting ferroptosis. This strongly suggests that managing iron overload and preventing the Fenton reaction is a critical therapeutic lever in acute ocular pathologies.

B. Ferroptosis and Diabetic Retinopathy (DR)

Diabetic Retinopathy (DR) is a chronic microvascular disease driven by persistent hyperglycemia. Ferroptosis contributes to DR pathogenesis, illustrating how chronic metabolic stress funnels into this specific cell death pathway. Research into DR models has identified potential molecular targets for intervention, such as the regulation of the GPX4-Yes-associated protein (YAP) signaling pathway by pipecolic acid, which successfully alleviates ferroptosis in this context. Furthermore, in proliferative DR, there is an established relationship between the upregulation of heme oxygenase 1 (HMOX1), M2 macrophage infiltration, and ferroptosis, indicating a complex intersection between ferroptotic cell death and the inflammatory cascade.

C. Shared Upstream Stressors: The Role of LCN2

A key connection between various ocular pathologies is the involvement of Lipocalin 2 (LCN2). Studies on RIR injury have demonstrated that overexpressed LCN2 exacerbates retinal damage and visual function impairment by promoting Retinal Ganglion Cell (RGC) death through ferroptosis. The involvement of LCN2 in both ischemic retinopathy and dry AMD pathogenesis (where it activates inflammasome-ferroptosis processes ) suggests that this inflammatory mediator acts as a common upstream pathway converging on ferroptosis. This convergence provides an opportunity for a broader neuroprotective strategy across multiple retinal disorders by targeting LCN2 signaling.

IV. Ferroptosis and Age-Related Macular Degeneration (AMD) Pathogenesis

Ferroptosis is not merely a bystander in AMD but represents a central, mechanistic explanation for RPE dysfunction and subsequent photoreceptor loss. The specific biochemical stressors present in the macula directly activate this death pathway.

A. Pathological Correlation with Ferroptotic Death

The main pathological feature of dry AMD is the characterized by RPE damage, the presence of drusen, and progressive Geographic Atrophy (GA), leading to the death of photoreceptors. Ferroptosis, along with pyroptosis, apoptosis, necroptosis, and autophagy, contributes substantially to this pattern of retinal cell demise.

A specific link exists between ferroptosis and drusen formation. Drusen are yellowish deposits that form between the RPE and the Bruch membrane. Their formation is strongly attributed to the failure of RPE cells to efficiently phagocytize and digest the shed photoreceptor outer segments (POS). When RPE cells are under chronic ferroptotic stress, their critical phagocytic ability is impaired. The resulting accumulated corpuscles cannot be cleared in time and deposit in the Bruch membrane. This functional impairment driven by ferroptotic stress provides a crucial link between regulated cell death and the earliest clinical features of AMD pathology.

B. Specific Molecular Drivers in AMD

The specific environment of the aging macula provides several potent, convergent drivers of ferroptosis:

1. Toxic Retinoid Accumulation

A key metabolic insult in dry AMD (dAMD) and Stargardt disease type 1 (STGD1) is the disruption of the retinoid (visual) cycle, which leads to the rapid and excessive accumulation of all-trans-retinal (atRAL) in photoreceptors and RPE. Studies using mouse models confirmed that atRAL accumulation clearly induces ferroptosis in the RPE. The protective effect observed when ferroptosis is inhibited suggests that atRAL toxicity acts as a direct molecular trigger for ferroptotic cell death, thereby contributing to RPE failure and the subsequent cascade of photoreceptor degeneration.

2. Chronic Iron Overload

The chronic oxidative stress induced by aging and phagocytic demands, combined with abnormal iron accumulation in the retina of AMD patients , provides the perfect environment for sustained ferroptosis. The oxidation of excessive ferrous iron (Fe2+) catalyzes the formation of highly reactive ROS through the Fenton reaction, overwhelming cellular defenses and initiating the catastrophic lipid peroxidation signature of ferroptosis. This establishes iron dysregulation as a necessary, non-redundant factor in AMD pathogenesis.

3. Inflammasome-Autophagy-Ferroptosis Axis

The interaction between inflammation and cell death is crucial in AMD. Increased levels of Lipocalin 2 (LCN2) in the RPE have been shown to decrease protective autophagy while simultaneously activating inflammasome-ferroptosis processes in dry AMD mouse models. This molecular axis suggests a pathway by which chronic inflammatory signals can suppress the RPE’s waste-clearing capacity (autophagy) while activating the terminal ferroptotic death pathway, resulting in accelerated degeneration.

V. Therapeutic Strategies Targeting Ferroptosis in AMD

The mechanical confirmation that ferroptosis drives RPE and photoreceptor loss has opened a novel therapeutic window. Strategies focus on direct antioxidant scavenging, iron management, and overcoming the severe translational challenge of drug delivery.

A. Small Molecule Ferroptosis Inhibitors: Radical-Trapping Antioxidants (RTAs)

The most established class of ferroptosis inhibitors includes Ferrostatin-1 (Fer-1) and Liproxstatin-1 (Lip-1).Mechanistic studies reveal that these compounds function as potent Radical-Trapping Antioxidants (RTAs). They exert their protective effect by reacting with and neutralizing lipid peroxyl radicals, thereby breaking the destructive chain reaction of lipid peroxidation. This action is independent of direct enzymatic inhibition, such as that targeted by inhibitors of 15-Lipoxygenase (15-LOX-1). The superior reactivity of Fer-1 and Lip-1 compared to natural antioxidants like α-tocopherol (α-TOH) in lipid environments underscores their potency in subverting ferroptosis.

Preclinical Validation in AMD

The therapeutic potential of this approach has received strong preclinical validation. In light-exposed Abca4−/−Rdh8−/− mice, a model highly relevant to dAMD and STGD1 due to atRAL accumulation, intraperitoneal administration of Ferrostatin-1 effectively mitigated the degeneration of the RPE and photoreceptors. This resulted in a significant amelioration of retinal function, providing compelling proof-of-concept that inhibiting ferroptosis can successfully halt the neurodegenerative cascade in inherited and age-related macular diseases.

B. Complementary Strategies: Iron Chelation and Upstream Modulation

Given that iron dependency is central to the ferroptosis mechanism, iron chelators remain a critical therapeutic modality. The success of Deferoxamine in alleviating RIR injury validates iron chelation as a viable strategy in ocular disease. Furthermore, the observation that the protective effects of Liproxstatin-1 include regulating ferroptosis-related iron proteins (Transferrin (TF), Ferritin (Fth), and Ferritin Mitochondrial (FtMt)) suggests that the most effective future AMD therapies may combine RTA activity with robust iron homeostasis management.

Additionally, upstream targeting of inflammatory signals, specifically inhibiting LCN2, offers a unique opportunity to simultaneously reverse RPE dysfunction, enhance autophagy, and prevent the activation of the ferroptosis cascade in dry AMD models.

C. Advanced Drug Delivery and Nanotechnology

Despite promising preclinical efficacy, the major translational obstacle for hydrophobic ferroptosis inhibitors (such as Fer-1 and Lip-1) is achieving sustained, therapeutic concentrations at the RPE/retinal interface. Systemic delivery, as used in mouse models , is not feasible for chronic human therapy.

The rapid development of nanotechnology provides a critical path forward. Nanoparticles (NPs) can serve as carriers to overcome the limitations of traditional, small-molecule drugs. By encapsulating RTAs, NPs can be engineered for targeted delivery to the posterior segment, increasing bioavailability and ensuring sustained drug residence time at the site of pathology (the RPE).

The development of these nanosystems requires stringent criteria to ensure clinical relevance. It is essential to confirm that NP-mediated protection is specifically due to ferroptosis inhibition (e.g., through RTA or iron chelation action) rather than generalized anti-ROS effects or non-specific nanotoxicity. This distinction mandates the use of lipophilic radical-trapping antioxidants (Fer-1, Lip-1), iron chelators, and evaluation of effects on key ferroptotic markers, such as GPX4 activity.

Table 2: Preclinical Ferroptosis Inhibitors and Therapeutic Targets in Ocular Pathology

Agent	Classification	Primary Molecular Target/Action	Ocular Disease Application/Model	Source Reference
Ferrostatin-1 (Fer-1)	Radical-Trapping Antioxidant (RTA)	Direct scavenging of lipid peroxyl radicals	Mitigated RPE/photoreceptor degeneration (dAMD/STGD1 mouse model)
Liproxstatin-1 (Lip-1)	Radical-Trapping Antioxidant (RTA)	Direct scavenging of lipid peroxyl radicals; regulates iron proteins	Preclinical efficacy in neuroinflammation
Deferoxamine	Iron Chelator	Sequesters intracellular free iron (Fe2+)	Alleviates Retinal Ischemia-Reperfusion (RIR) injury
Pipecolic acid	Signaling Regulator	Regulates GPX4-Yes-associated protein (YAP) signaling	Alleviates ferroptosis in Diabetic Retinopathy (DR)
LCN2 Modulation (Inhibition)	Upstream Regulator Target	Blocks activation of inflammasome-ferroptosis axis; enhances autophagy	Potential target for dry AMD and RIR injury

VI. Future Directions and Translational Research Priorities

The clinical success of ferroptosis inhibition in AMD depends heavily on establishing reliable, non-invasive methods for diagnosis and monitoring of active ferroptosis in human patients.

A. Discovery and Validation of Specific Ocular Ferroptosis Biomarkers

There is a critical need to develop cost-effective, validated biomarker panels that reflect the active ferroptotic state within the eye. Such panels should assess the three principal indicators of ferroptosis:

1. Lipid Peroxidation Products

Measuring lipid peroxidation products, such as Malondialdehyde (MDA) and 4-Hydroxynonenal (4-HNE), in accessible ocular biofluids (e.g., vitreous or aqueous humor) or through imaging provides direct evidence of oxidative damage characteristic of ferroptosis. A negative correlation between reducing power and the number of 4-HNE-positive cells can confirm active ferroptosis status in vivo.

2. Iron Homeostasis Markers

Quantifying the levels and regulatory status of key iron-related proteins, such as ferritin and transferrin, can indicate iron dysregulation and cellular susceptibility to ferroptosis.

3. Antioxidant Capacity

Assaying for localized Glutathione (GSH) depletion or quantifying the inhibition status of GPX4 can confirm the failure of the primary cellular defense mechanisms. The identification of these biomarkers requires high-throughput screening and validation using appropriate models that faithfully represent the chronic nature of AMD pathology.

B. Non-Invasive Detection and Monitoring

For effective patient stratification in clinical trials and long-term management, non-invasive imaging techniques must be developed to monitor ferroptosis progression. Electron Paramagnetic Resonance Imaging (EPRI) offers a promising avenue for redox imaging in vivo.

EPRI allows for the non-invasive detection of tumor redox status and could be adapted to monitor retinal redox changes. The ability to quantify the shift in reducing power and correlate it directly with markers of lipid peroxidation (like 4-HNE) would provide an unprecedented tool for diagnosing active ferroptosis and assessing the efficacy of RTA-based therapies. Implementing cost-effective validation strategies and collaborating across specialized fields are essential steps to translate these advanced detection methods into affordable, scalable research and clinical practice.

Table 3: Translational Biomarkers for Detection and Monitoring of Ocular Ferroptosis

Biomarker Category	Specific Markers	Molecular Significance	Measurement/Detection Method	Source Reference
Lipid Peroxidation Products	Malondialdehyde (MDA), 4-Hydroxynonenal (4-HNE)	Direct measure of oxidative damage and active ferroptosis	Ocular fluid analysis; Non-invasive Redox Imaging (EPRI)
Iron Homeostasis	Ferritin, Transferrin	Reflects iron availability and regulatory failure	Ocular fluid analysis; Tissue assay
Antioxidant Capacity	Glutathione (GSH) levels, GPX4 activity	Indicates depletion of cellular defense mechanisms	Tissue biopsy/cellular assay

VII. Conclusions

Ferroptosis is established as a central and mechanistically distinct form of regulated cell death that is fundamentally implicated in the pathogenesis of Age-related Macular Degeneration and other severe ocular disorders, including Diabetic Retinopathy and Retinal Ischemia-Reperfusion injury.

In AMD, ferroptosis acts as a convergence point for major pathogenic factors, including chronic iron dysregulation, the metabolic toxicity induced by all-trans-retinal (atRAL) accumulation, and inflammatory signaling mediated by LCN2. The failure of the RPE’s primary antioxidant defenses (GPX4 and FSP1) in the face of excessive lipid peroxidation and Fe2+ catalysis drives RPE demise, directly contributing to drusen formation and subsequent photoreceptor loss.

Preclinical evidence using small molecule Radical-Trapping Antioxidants (RTAs), such as Ferrostatin-1, provides compelling proof-of-concept for therapeutic intervention in AMD models. The future of ferroptosis-targeted therapy hinges on overcoming significant translational hurdles, namely through the development of specialized nanoparticle delivery systems capable of achieving sustained, targeted distribution to the RPE layer. Equally critical for clinical viability is the validation of robust, non-invasive diagnostic tools, such as specific ocular biomarker panels (MDA, 4-HNE, iron proteins) and advanced imaging modalities like Electron Paramagnetic Resonance Imaging (EPRI), to accurately detect and monitor the ferroptotic process in vivo. Success in these translational areas is essential to bring this neuroprotective strategy forward for clinical application.

References:

mdpi.com

Ferroptosis: An Energetic Villain of Age-Related Macular ... - MDPI

frontiersin.org

Ferroptosis inhibitors: past, present and future - Frontiers

pmc.ncbi.nlm.nih.gov

Ferroptosis: Iron-mediated cell death linked to disease pathogenesis - PubMed Central

frontiersin.org

Ferroptosis in ocular diseases: mechanisms, crosstalk ... - Frontiers

pmc.ncbi.nlm.nih.gov

Lipocalin 2 induces visual impairment by promoting ferroptosis in retinal ischemia-reperfusion injury - PubMed Central

mdpi.com